Curing Tumor Genetic Mutations with Efficient Immune Checkpoint Inhibitors

Cancer cell

The quantity of mutations in a tumor‘s genome may foresee how well a patient will benefit by treatment with immune checkpoint inhibitors, drugs that take the brakes off the immune system. Albeit past research has just shown that higher tumor mutational burden (TMB) is attached to better treatment results, recent work, which incorporates information from in excess of 1,600 patients over various cancers, gives probably the most grounded and nittiest gritty proof for the connection yet.

Checkpoint inhibitor drugs work by blocking protein receptors that direct the action of T cells and other immune system segments, in this manner boosting these cells’ antitumor action. Bristol-Myers Squibb’s nivolumab (Opdivo) and Merck’s pembrolizumab (Keytruda) have gained ground in clinical preliminaries generally, with the last treatment accepting administrative endorsement from the US Food and Drug Administration in 2018.


Samstein, R. M., et al. (2019). “Tumor mutational load predicts survival after immunotherapy across multiple cancer types.” Nat Genet.

Leave a Reply